3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
The diagnosis is often made on bowel resected as an emergency for perforation or obstruction. Where there is time, it is made at endoscopy with biopsies of the small bowel. Coeliac disease is confirmed or newly diagnosed at the same time, and the rest of the family is offered testing. Staging uses the gastrointestinal system that counts depth and node involvement, and imaging of the whole abdomen matters because disease is often multifocal.
Histopathology examines tissue under a microscope. Immunohistochemistry uses antibodies to show selected antigens; both need specimen context and appropriate interpretation.
FDG PET images the distribution of a radioactive glucose analogue. Normal tissues, inflammation and some cancers can take it up, so a bright area is not a diagnosis of cancer.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Most patients are malnourished before the lymphoma starts, because the coeliac disease has been damaging the bowel, and the bowel is at risk of perforating during treatment. Nutritional assessment and support, often intravenous, and early involvement of a surgeon are part of the treatment rather than an afterthought, and they determine what chemotherapy is possible. A strict gluten-free diet is continued throughout.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
In the population-based series from northern England and Scotland, the 54 patients diagnosed between 1994 and 1998, of whom 35 had chemotherapy (mostly anthracycline-based) with or without surgery and 19 had surgery alone, had a median progression-free survival of 3.4 months and overall survival of 7.1 months. From 1998 the same group gave patients fit enough for it ifosfamide, etoposide and epirubicin alternating with methotrexate, followed by an autologous stem cell transplant; in 26 patients treated that way, five-year progression-free survival was 52 per cent and overall survival 60 per cent. That is a comparison against a historical group from the same region rather than a randomised trial; a 2026 paper summarises the later prospective United Kingdom phase 2 study of the approach as showing more modest outcomes, with one-year survival of 45 per cent. NCI PDQ calls the evidence for transplant consolidation anecdotal. A clinical trial is a reasonable first choice.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.
The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.
Autologous stem cell transplant collects the patient's own blood-forming stem cells, gives melphalan or another chemotherapy at a dose that would otherwise destroy the marrow, then returns the cells to rebuild it. It is standard consolidation in myeloma and for relapsed lymphoma, though CAR-T has displaced it in early-relapsing large B-cell lymphoma.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Febrile neutropenia (with doxorubicin) · EORTC 62012, intensified doxorubicin plus ifosfamide arm (103 of 224); 13% with doxorubicin alone | - | 46% |
| Central nervous system toxicity, including encephalopathy · Ifosfamide monotherapy trials pooled in the label (154 of 1001) | 15.4% | - |
| Visible blood in the urine (macroscopic haematuria) · With mesna, ifosfamide monotherapy trials pooled in the label (5 of 97); 11.1% without mesna | 5.2% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.